Fwd: Ann Oncol Advance Access for September 22, 2016

Advance Access Alert 13 September 2016 to 22 September 2016

Original articles Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study P. Vuylsteke, M. Huizing, K. Petrakova, R. Roylance, R. Laing, S. Chan, F. Abell, S. Gendreau, I. Rooney, D. Apt, J. Zhou, S. Singel, and L. Fehrenbacher Ann Oncol published 29 August 2016, 10.1093/annonc/mdw320 [Abstract] [Full Text] [PDF] [Supplementary Data] [Request Permissions] The PEGGY study failed to meet its primary end point, with no improvement in progression-free survival in patients who received pictilisib plus paclitaxel versus placebo plus paclitaxel in either the intention-to-treat population or in patients with PIK3CA-mutated tumours. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial M. Ikeda, S. Shimizu, T. Sato, M. Morimoto, Y. Kojima, Y. Inaba, A. Hagihara, M. Kudo, S. Nakamori, S. Kaneko, R. Sugimoto, T. Tahara, T. Ohmura, K. Yasui, K. Sato, H. Ishii, J. Furuse, and T. Okusaka Ann Oncol published 29 August 2016, 10.1093/annonc/mdw323 [Abstract] [Full Text] [PDF] [Supplementary Data] OPEN ACCESS In a randomized phase II study of sorafenib plus hepatic arterial infusion chemotherapy with cisplatin in comparison with sorafenib alone in patients with advanced hepatocellular carcinoma, it yielded favorable overall survival when compared with sorafenib alone. This is the first report of its effectiveness in relation to the overall survival in comparison with that of sorafenib alone in patients with advanced hepatocellular carcinoma. Clinical Outcomes of Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitor, or Conventional Chemotherapy K.A. Ahmed, Y.A. Abuodeh, M.I. Echevarria, J.A. Arrington, D.G. Stallworth, C. Hogue, A.O. Naghavi, S. Kim, Y. Kim, B.G. Patel, S. Sarangkasiri, P.A.S. Johnstone, S. Sahebjam, N.I. Khushalani, P.A. Forsyth, L.B. Harrison, M. Yu, A.B. Etame, and J.J. Caudell Ann Oncol published 15 September 2016, 10.1093/annonc/mdw417 [Abstract] [PDF] [Supplementary Data] [Request Permissions] Novel targeted and immunotherapeutic agents have revolutionized systemic melanoma management. We note differing rates of distant brain control as well as overall survival following systemic treatment and stereotactic radiosurgery (SRS) in melanoma brain metastases management. This data supports further research to determine the potential synergistic effect between these agents with SRS. Review Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape K. A. Olaussen and S. Postel-Vinay Ann Oncol published 8 August 2016, 10.1093/annonc/mdw321 [Abstract] [Full Text] [PDF] [Request Permissions] The majority of non-small-cell lung cancer (NSCLC) tumours do not present targetable driver mutations, and <25% of NSCLC patients derive benefit from immunotherapy. Therefore, conventional cytotoxic chemotherapy (CCC) remains the cornerstone treatment of NSCLC patients. Predictive biomarkers of conventional cytotoxic chemotherapy are still lacking in NSCLC because of a strikingly high attrition rate between promising pre-clinical data and negative clinical results. Not even a handful of biomarkers are still in the race, and none are ready for implementation in clinical practice. The main causes of failure and future perspectives will be discussed in this review. corrigendum Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression U. Nitz, O. Gluz, J. Huober, H. H. Kreipe, R. E. Kates, A. Hartmann, R. Erber, Z. Moustafa, M. Scholz, B. Lisboa, S. Mohrmann, V. Möbus, D. Augustin, G. Hoffmann, E. Weiss, S. Böhmer, R. Kreienberg, A. Du Bois, D. Sattler, C. Thomssen, M. Kiechle, F. Jänicke, D. Wallwiener, N. Harbeck, and W. Kuhn Ann Oncol published 15 September 2016, 10.1093/annonc/mdw349 [Extract] [Full Text] [PDF] [Request Permissions] Letter to the Editor Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis S.-K. Myung Ann Oncol published 13 September 2016, 10.1093/annonc/mdw294 [Extract] [Full Text] [PDF] [Request Permissions] special article Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice S. Michiels, N. Ternès, and F. Rotolo Ann Oncol published 15 September 2016, 10.1093/annonc/mdw307 [Abstract] [Full Text] [PDF] OPEN ACCESS

This message was sent to alsfakia@gmail.com To unsubscribe from or edit your subscriptions to this service, go to http://ift.tt/2cDDvPP.org/cgi/alerts/etoc Or by mail: Customer Service * 425 Broadway St * Redwood City, CA 94063 * U.S.A.

http://ift.tt/2cVTWXu